紫杉醇、卡铂和贝伐珠单抗治疗晚期或复发性宫颈癌的II期试验
该II期试验评估紫杉醇、卡铂和贝伐珠单抗联合方案用于无法根治性手术或放疗的晚期或复发性宫颈癌患者,共34例接受治疗,客观缓解率为88%(95%CI 72.5%-96.7%),中位随访18.5个月,结论认为该联合方案有效且安全。
要点
- 34例晚期或复发性宫颈癌患者接受紫杉醇+卡铂+贝伐珠单抗治疗,客观缓解率88%。
- 完全缓解17例(50%),部分缓解13例(38%),中位缓解持续时间6个月。
- 3-4级中性粒细胞减少和白细胞减少各14例(41.2%),1例既往盆腔放疗者发生2级直肠阴道瘘。
核心结论
- 紫杉醇、卡铂和贝伐珠单抗联合方案在晚期或复发性宫颈癌患者中有效且安全。
研究设计与样本
- II期试验,纳入无法根治性手术或放疗的晚期或复发性宫颈癌患者,共34例接受治疗。
- 治疗方案为紫杉醇175 mg/m2、卡铂曲线下面积6 mg/mL/min、贝伐珠单抗15 mg/kg,每21天一次,直至疾病进展、完全缓解或出现限制性毒性。
- 主要终点为客观缓解。
主要发现
- 34例患者接受中位6个治疗周期(范围2-25),中位随访18.5个月(范围2-29)。
- 客观缓解率为88%(95%CI 72.5%-96.7%)。
- 17例(50%)完全缓解,13例(38%)部分缓解,中位缓解持续时间6个月。
- 3-4级血液学毒性:中性粒细胞减少14例(41.2%)、白细胞减少14例(41.2%)、贫血11例(32.4%)、血小板减少9例(26.5%)。
- 1例既往接受盆腔放疗的患者发生2级直肠阴道瘘。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We evaluated the efficacy and safety of the combination of paclitaxel, carboplatin, and bevacizumab in patients with advanced or recurrent cervical cancer. METHODS: Subjects included patients with advanced or recurrent cervical cancer not amenable to curative treatment with surgery or radiation therapy. Treatment consisted of paclitaxel 175 mg/m2, carboplatin area under the curve 6 mg/mL/min, and bevacizumab 15 mg/kg every 21 days until disease progression, complete remission, or limiting toxicity. The primary endpoint was the objective response. RESULTS: In total, 34 patients received a median of 6 treatment cycles (range 2-25). The median follow-up period was 18.5 months (range 2-29). The objective response was 88% (95% confidence interval: 72.5%-96.7%). Seventeen patients (50%) experienced complete response, whereas 13 patients experienced (38%) partial response with a median duration of 6 months. Grades 3 and 4 hematologic toxicities manifested as neutropenia in 14 (41.2%), leukopenia in 14 (41.2%), anemia in 11 (32.4%), and thrombocytopenia in 9 (26.5%) patients. One patient who underwent prior pelvic irradiation developed grade 2 rectovaginal fistula. CONCLUSION: The combination of paclitaxel, carboplatin, and bevacizumab is effective and safe in patients with advanced or recurrent cervical cancer.
引用
- Suzuki K, Nagao S, Shibutani T, et al. Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer. Gynecol Oncol. 2019. PMID: 31285082. doi:10.1016/j.ygyno.2019.05.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。